July 01, 2011
Joe Edelman says investor biases create opportunities for his health care and biotech fund, Perceptive Advisors
In his first job as a junior biotech analyst in a small New York brokerage house, Joe Edelman spotted a company he was convinced would self-destruct. Cambridge BioScience of Worcester, Mass., had developed a five-minute AIDS test in the late …
*free trial allows access to online content excluding research, rankings and data.
Subscribers have unlimited access to all online content inc rankings. Start your subscription today - click on the button below.
Taking a free trial will give you access to online content one week (excludes research & rankings). Start your trial today.
Will a Trump presidency be good for hedge funds?
View previous results
All material subject to strictly enforced copyright laws. ©
Euromoney Institutional Investor PLC.
Sorry, you are not allowed to print this article.
Please contact us if you have any inquiry.